NCT02494284 (STAMP-DES) is a Phase 4 clinical trial of Clopidogrel in Coronary Artery Disease, sponsored by CHEOL WHAN LEE, M.D., Ph.D.

Who is sponsoring NCT02494284?

NCT02494284 is sponsored by CHEOL WHAN LEE, M.D., Ph.D.

What drugs are being tested in NCT02494284?

Interventions in NCT02494284: Clopidogrel, Aspirin plus clopidogrel.

What condition does NCT02494284 study?

NCT02494284 studies Coronary Artery Disease.

Is NCT02494284 still recruiting?

NCT02494284 is currently terminated. Last updated 23 February 2017.

Last reviewed 2017-02-23 · How we verify

NCT02494284: STAMP-DES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Terminated Phase 4 Last updated 23 February 2017

What this trial tests

Phase 4 trial testing Clopidogrel in Coronary Artery Disease in 364 participants. Terminated before completion.

Timeline

22 December 2015

Primary endpoint
13 February 2017

13 February 2017

Quick facts

Lead sponsor	CHEOL WHAN LEE, M.D., Ph.D
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	364
Start date	22 December 2015
Primary completion	13 February 2017
Estimated completion	13 February 2017
Sites	12 locations across South Korea

Drugs / interventions tested

Clopidogrel (clopidogrel) — full drug profile →
Aspirin plus clopidogrel — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

CHEOL WHAN LEE, M.D., Ph.D — full company profile →

Who can join

19 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare short-term (6-month Dual Anti Platelet Therapy(DAPT) followed by clopidogrel monotherapy) vs. standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy) on clinically relevant bleeding complications (Bleeding Academic Research Consortium(BARC) type 2, 3, or 5)31 in patients after zotarolimus-eluting stent implantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.
Cho MS, Park DW. · · 2017 · cited 5× · PMID 28823143 · DOI 10.3904/kjim.2016.391

Verify or expand the search:

Other trials of Clopidogrel

Trials testing the same drug.

NCT07012629 — A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in P · Phase 3 · recruiting
NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
NCT07040787 — Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other CHEOL WHAN LEE, M.D., Ph.D trials

Trials by the same sponsor.

NCT04330079 — Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Dis · Phase 4 · terminated
NCT03208465 — Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coron · Phase 4 · completed
NCT02978456 — Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02494284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CHEOL WHAN LEE, M.D., Ph.D
Last refreshed: 23 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02494284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing